Innova Therapeutics Acquires Enci Therapeutics’ IVT-8086 Cancer Program
Innova Therapeutics announced the acquisition of Enci Therapeutics, gaining its primary cancer therapeutic program IVT‑8086,...
Innova Therapeutics announced the acquisition of Enci Therapeutics, gaining its primary cancer therapeutic program IVT‑8086,...
Kelonia Therapeutics announced a strategic collaboration with Johnson & Johnson (J&J, NYSE: JNJ) to develop...
Jiangxi Rimag Group Co., Ltd. (HKG: 2522) announced a Strategic Framework Cooperation Agreement with the...
Biogen Inc. (NASDAQ: BIIB) and Dayra Therapeutics announced a research collaboration to discover and develop...
HBM Holdings Limited (HKG: 2142) announced the renewal and deepening of its global strategic collaboration...
Phrontline Biopharma, a next‑generation antibody‑drug conjugate (ADC) company, announced the close of an oversubscribed USD...
Valo Health, Inc. announced a strategic collaboration with Merck KGaA (ETR: MRK) to advance therapeutic...
3SBio Inc. (HKG: 1530) announced plans to spin off its consumer healthcare subsidiary Mandi International...
GE HealthCare (NASDAQ: GEHC) announced a definitive agreement to acquire Intelerad Medical System for USD...
Abbott Laboratories (NYSE: ABT) and Exact Sciences Corp. (NASDAQ: EXAS) announced a definitive agreement under...
Freenome, a California‑based early cancer detection company, announced a strategic collaboration with Roche (SWX: ROG,...
Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), announced a non‑exclusive licensing...
Rock Roc Biotechnology Co., Ltd completed an oversubscribed RMB 50 million (≈ US$7 million) Series A financing to...
Mirxes Holding Company Limited (HKG: 2629) and Walvax Biotechnology Co., Ltd. (300142.SZ) signed a Memorandum...
Gate Bioscience announced the close of its oversubscribed USD 65 million Series B financing led by...
Resight Therapeutics, a China‑based cell‑therapy pioneer founded in September 2024, announced the close of an Angel‑stage...
Johnson & Johnson (J&J, NYSE: JNJ) announced a definitive agreement to acquire Halda Therapeutics in an all‑cash...
Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA: 688266) announced plans to de‑register and cancel its U.S. subsidiary,...
Merck Sharp & Dohme Inc. (MSD, NYSE: MRK) disclosed a definitive acquisition agreement with Cidara Therapeutics, Inc....
BrightGene BrightGene Bio-Medical Techonology (Suzhou) Co., Ltd. (SHA: 688166) disclosed a RMB 50 million (≈ US$7.2 million) capital increase...